Literature DB >> 25139337

Single-nucleotide polymorphism associations in common with immune responses to measles and rubella vaccines.

Inna G Ovsyannikova1, Hannah M Salk, Beth R Larrabee, V Shane Pankratz, Gregory A Poland.   

Abstract

Single-nucleotide polymorphisms (SNPs) in candidate immune response genes were evaluated for associations with measles- and rubella-specific neutralizing antibodies, interferon (IFN)-γ, and interleukin (IL)-6 secretion in two separate association analyses in a cohort of healthy immunized subjects. We identified six SNP associations shared between the measles-specific and rubella-specific immune responses, specifically neutralizing antibody titers (DDX58), secreted IL-6 (IL10RB, IL12B), and secreted IFN-γ (IFNAR2, TLR4). An intronic SNP (rs669260) in the antiviral innate immune receptor gene, DDX58, was significantly associated with increased neutralizing antibody titers for both measles and rubella viral antigens post-MMR vaccination (p values 0.02 and 0.0002, respectively). Significant associations were also found between IL10RB (rs2284552; measles study p value 0.006, rubella study p value 0.00008) and IL12B (rs2546893; measles study p value 0.005, rubella study p value 0.03) gene polymorphisms and variations in both measles- and rubella virus-specific IL-6 responses. We also identified associations between individual SNPs in the IFNAR2 and TLR4 genes that were associated with IFN-γ secretion for both measles and rubella vaccine-specific immune responses. These results are the first to indicate that there are SNP associations in common across measles and rubella vaccine immune responses and that SNPs from multiple genes involved in innate and adaptive immune response regulation may contribute to the overall human antiviral response.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139337      PMCID: PMC4198472          DOI: 10.1007/s00251-014-0796-z

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  31 in total

1.  The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Robert M Jacobson; Gregory A Poland
Journal:  Hum Hered       Date:  2011-11-11       Impact factor: 0.444

2.  The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes in measles vaccine immunity.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Hum Genet       Date:  2011-03-19       Impact factor: 4.132

3.  Multigenic control of measles vaccine immunity mediated by polymorphisms in measles receptor, innate pathway, and cytokine genes.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Megan M O'Byrne; Robert M Jacobson; V Shane Pankratz; Gregory A Poland
Journal:  Vaccine       Date:  2012-01-20       Impact factor: 3.641

4.  Associations between single nucleotide polymorphisms and haplotypes in cytokine and cytokine receptor genes and immunity to measles vaccination.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-08-27       Impact factor: 3.641

5.  Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in healthy vaccinees.

Authors:  Neelam Dhiman; Iana H Haralambieva; Robert A Vierkant; V Shane Pankratz; Jenna E Ryan; Robert M Jacobson; Inna G Ovsyannikova; Gregory A Poland
Journal:  Cytokine       Date:  2010-02-01       Impact factor: 3.861

6.  Associations between polymorphisms in the antiviral TRIM genes and measles vaccine immunity.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Gregory A Poland
Journal:  Hum Immunol       Date:  2013-02-13       Impact factor: 2.850

7.  Effects of vitamin A and D receptor gene polymorphisms/haplotypes on immune responses to measles vaccine.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Robert M Jacobson; Gregory A Poland
Journal:  Pharmacogenet Genomics       Date:  2012-01       Impact factor: 2.089

8.  RIG-I is required for the inhibition of measles virus by retinoids.

Authors:  Kaitlin J Soye; Claire Trottier; Chris D Richardson; Brian J Ward; Wilson H Miller
Journal:  PLoS One       Date:  2011-07-19       Impact factor: 3.240

9.  Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Benjamin J Umlauf; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-09-20       Impact factor: 3.641

10.  2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.

Authors:  Iana H Haralambieva; Neelam Dhiman; Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Hum Immunol       Date:  2010-01-31       Impact factor: 2.850

View more
  14 in total

Review 1.  Vaccine-Drug Interactions: Cytokines, Cytochromes, and Molecular Mechanisms.

Authors:  Paolo Pellegrino; Cristiana Perrotta; Emilio Clementi; Sonia Radice
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

2.  Single nucleotide polymorphisms/haplotypes associated with multiple rubella-specific immune response outcomes post-MMR immunization in healthy children.

Authors:  Inna G Ovsyannikova; Hannah M Salk; Beth R Larrabee; V Shane Pankratz; Gregory A Poland
Journal:  Immunogenetics       Date:  2015-09-02       Impact factor: 2.846

3.  Associations between markers of cellular and humoral immunity to rubella virus following a third dose of measles-mumps-rubella vaccine.

Authors:  Stephen N Crooke; Inna G Ovsyannikova; Richard B Kennedy; Nathaniel D Warner; Gregory A Poland
Journal:  Vaccine       Date:  2020-11-04       Impact factor: 3.641

Review 4.  The science and medicine of human immunology.

Authors:  Bali Pulendran; Mark M Davis
Journal:  Science       Date:  2020-09-25       Impact factor: 47.728

Review 5.  Variability in Humoral Immunity to Measles Vaccine: New Developments.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Jennifer A Whitaker; Gregory A Poland
Journal:  Trends Mol Med       Date:  2015-11-18       Impact factor: 11.951

6.  Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment.

Authors:  Naixue Yang; Fansen Ji; Liqing Cheng; Jingzhe Lu; Xiaofeng Sun; Xin Lin; Xun Lan
Journal:  NPJ Precis Oncol       Date:  2021-05-07

Review 7.  Does Rubella Cause Autism: A 2015 Reappraisal?

Authors:  Jill Hutton
Journal:  Front Hum Neurosci       Date:  2016-02-01       Impact factor: 3.169

8.  Potential role of killer immunoglobulin receptor genes among individuals vaccinated against hepatitis B virus in Lebanon.

Authors:  Nada M Melhem; Rami A Mahfouz; Khalil Kreidieh; Rabab Abdul-Khalik; Rolla El-Khatib; Reem Talhouk; Umayya Musharrafieh; Ghassan Hamadeh
Journal:  World J Hepatol       Date:  2016-10-18

9.  In silico Analysis Revealed High-risk Single Nucleotide Polymorphisms in Human Pentraxin-3 Gene and their Impact on Innate Immune Response against Microbial Pathogens.

Authors:  Raman Thakur; Jata Shankar
Journal:  Front Microbiol       Date:  2016-02-23       Impact factor: 5.640

Review 10.  Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.

Authors:  Sacha Gnjatic; Vincenzo Bronte; Laura Rosa Brunet; Marcus O Butler; Mary L Disis; Jérôme Galon; Leif G Hakansson; Brent A Hanks; Vaios Karanikas; Samir N Khleif; John M Kirkwood; Lance D Miller; Dolores J Schendel; Isabelle Tanneau; Jon M Wigginton; Lisa H Butterfield
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.